Search

Displaying all 3 results
DrugBest match

Selexipag

go.drugbank.com/drugs/DB11362
ApprovedInvestigational

Selexipag was approved by the United States FDA on December 22, 2015 for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression and reduce risk of hospitalization. PAH is a relatively rare disease with usually a poor prognosis requiring more treatment options to prolong long-term outcome...

  1. Pathway

    Selexipag Action Pathway

    smpdb.ca/view/SMP0126508
    Drug action

    Selexipag is a non-prostanoid prostacyclin receptor agonist, also known as Uptravi typically used to treat pulmonary arterial hypertension. … Selexipag is a selective prostacyclin receptor agonist, it is administered orally and is metabolized by carboylesterase1 into its active metabolite (ACT-333679).

    Drugs: Calcium · Magnesium cation · Cyclic adenosine monophosphate
  2. Indication

    Pulmonary arterial hypertension WHO functional class I

    go.drugbank.com/conditions/DBCOND0160108
    Drugs: Ambrisentan · Selexipag · Sotatercept